Matches in Wikidata for { <http://www.wikidata.org/entity/Q63573752> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- Q63573752 description "assaig clínic" @default.
- Q63573752 description "clinical trial" @default.
- Q63573752 description "clinical trial" @default.
- Q63573752 description "clinical trial" @default.
- Q63573752 description "clinical trial" @default.
- Q63573752 description "ensaio clínico" @default.
- Q63573752 description "ensayo clínico" @default.
- Q63573752 description "ensayu clínicu" @default.
- Q63573752 description "essai clinique" @default.
- Q63573752 description "klinisch onderzoek" @default.
- Q63573752 description "клінічне випробування" @default.
- Q63573752 description "կլինիկական փորձարկում" @default.
- Q63573752 name "The XENERA™-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread" @default.
- Q63573752 type Item @default.
- Q63573752 label "The XENERA™-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread" @default.
- Q63573752 prefLabel "The XENERA™-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread" @default.
- Q63573752 P1132 Q63573752-E6118DF6-D88E-4B4B-BE7D-38B199DAC4C1 @default.
- Q63573752 P1476 Q63573752-F5D21D7E-4FC2-4380-859B-15A141BF357B @default.
- Q63573752 P17 Q63573752-11849FCF-3A43-4A28-8435-AFBDD748A219 @default.
- Q63573752 P17 Q63573752-41E24725-4185-4728-9572-B3ECA19D4F20 @default.
- Q63573752 P17 Q63573752-5EC42CF4-5E93-44F8-AD92-1199567F1958 @default.
- Q63573752 P17 Q63573752-6DCCFA2D-3750-49C1-8DCB-919981A57EBF @default.
- Q63573752 P17 Q63573752-82E36122-4C3D-47DD-952D-3E62BE7301A3 @default.
- Q63573752 P17 Q63573752-8C6066FF-4D22-4D80-A895-7AA97621A153 @default.
- Q63573752 P17 Q63573752-A0D31870-2B2F-470D-9408-335DF8CB36F2 @default.
- Q63573752 P17 Q63573752-B1665450-B2DF-4FAE-A4FB-CF79D5A0BC3E @default.
- Q63573752 P17 Q63573752-D07D42AA-2DB3-4373-810D-563A3F528CEB @default.
- Q63573752 P17 Q63573752-F5C95FA0-C0DC-45FB-84D2-40C9CDD99225 @default.
- Q63573752 P2899 Q63573752-D67D4880-161B-4194-9A10-EE1768EF8D87 @default.
- Q63573752 P3098 Q63573752-FD7A2216-B3A3-48F3-A6B8-3FB0ECB02248 @default.
- Q63573752 P31 Q63573752-252CCD0B-3D88-4AF2-9D96-84D8B7830ADA @default.
- Q63573752 P4844 Q63573752-2ABEC46F-A7EC-4FC5-872A-E850246939BA @default.
- Q63573752 P4844 Q63573752-B0C00E98-A031-4A87-AE87-6F6C0BF73954 @default.
- Q63573752 P4844 Q63573752-E579BC56-68DF-4396-ADDB-4BCF95BD5260 @default.
- Q63573752 P580 Q63573752-A8EBD3E7-335C-4E93-84B8-604968B89C89 @default.
- Q63573752 P582 Q63573752-3D0248CB-DED7-4FC3-80E0-C82AEA132384 @default.
- Q63573752 P6099 Q63573752-29998FB0-38A3-47A7-A474-FF03F1819BD8 @default.
- Q63573752 P6153 Q63573752-33C48113-8A2A-42C9-B3DA-096A4F907096 @default.
- Q63573752 P6153 Q63573752-4AA91E63-C72D-4EB1-A192-578A6CBED7A1 @default.
- Q63573752 P6153 Q63573752-5DFEFCCE-E85A-4827-BEB7-704E42260278 @default.
- Q63573752 P6153 Q63573752-6E2A4D5B-DDE3-4F82-908C-9239E9FF20D8 @default.
- Q63573752 P6153 Q63573752-8F89C671-E0CD-450F-B8C6-949F236C8E96 @default.
- Q63573752 P6153 Q63573752-A49DC9CE-7400-4251-BA7F-07AB1844E6A9 @default.
- Q63573752 P6153 Q63573752-CD953961-7C99-4415-9565-12AD9486EFC6 @default.
- Q63573752 P6153 Q63573752-EAFF6B16-0DDE-4A9B-A9BB-456313921DC4 @default.
- Q63573752 P6153 Q63573752-FBA3FFE5-63FA-4728-BE31-090DCBF7E230 @default.
- Q63573752 P8363 Q63573752-DFCCF2EC-E280-4D81-BB14-FE39F641A9F9 @default.
- Q63573752 P859 Q63573752-8BFE0FDA-4248-4EF8-9D5D-BBE203332678 @default.
- Q63573752 P1132 "+80" @default.
- Q63573752 P1476 "XENERA™-1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Post-menopausal Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease" @default.
- Q63573752 P17 Q142 @default.
- Q63573752 P17 Q16 @default.
- Q63573752 P17 Q183 @default.
- Q63573752 P17 Q29 @default.
- Q63573752 P17 Q30 @default.
- Q63573752 P17 Q31 @default.
- Q63573752 P17 Q38 @default.
- Q63573752 P17 Q408 @default.
- Q63573752 P17 Q41 @default.
- Q63573752 P17 Q45 @default.
- Q63573752 P2899 "+18" @default.
- Q63573752 P3098 "NCT03659136" @default.
- Q63573752 P31 Q30612 @default.
- Q63573752 P4844 Q32089 @default.
- Q63573752 P4844 Q418819 @default.
- Q63573752 P4844 Q421052 @default.
- Q63573752 P580 "2018-11-28T00:00:00Z" @default.
- Q63573752 P582 "2020-12-14T00:00:00Z" @default.
- Q63573752 P6099 Q42824440 @default.
- Q63573752 P6153 Q164946 @default.
- Q63573752 P6153 Q238101 @default.
- Q63573752 P6153 Q46992910 @default.
- Q63573752 P6153 Q4951532 @default.
- Q63573752 P6153 Q5031425 @default.
- Q63573752 P6153 Q50562360 @default.
- Q63573752 P6153 Q7063615 @default.
- Q63573752 P6153 Q833670 @default.
- Q63573752 P6153 Q87761729 @default.
- Q63573752 P8363 Q78089383 @default.
- Q63573752 P859 Q699532 @default.